Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Fibrobiologics, Inc.

FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Announces $25 Million Financing
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Engages Southern Star Research as CRO in Australia
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Files 2024 Second Quarter Report
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics to Present at JonesTrading Healthcare Summit 2024
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Set to Join Russell 2000® Index
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Announces 2024 Annual Meeting of Stockholders
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Files 2024 First Quarter Report
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics to Present at the BIO International Convention 2024
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
From Fibrobiologics, Inc.
Via GlobeNewswire
Tickers FBLG
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.